BioSpace News Archive

Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the Jefferies 2019 London Healthcare Conference on Wednesday and Thursday, November 20 and 21, 2019.

LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced it will present at the following upcoming healthcare conferences:

Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the appointment of Luisa Stamm, MD, PhD, as Chief Medical Officer.

BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced that Herm Cukier, Chief Executive Officer, will present at the upcoming Jefferies Global Healthcare Conference in London on November 20, 2019.

Presentation and panel session will focus on the impact of AI and genomics to revolutionize the oncology drug development process with a focus on Lantern’s next generation DNA damage repair inhibitor, LP184

Centene Corporation (NYSE: CNC) today issued a reminder that it will host an investor meeting, including a question-and-answer session, on Friday, December 13, 2019

$37.6M in Rubraca® (rucaparib) net product revenue for Q3 2019, up 65% year over year

Lantheus’ Value-Creating Vision for Integrating and Executing Transaction is Best Path Forward for Progenics

Data Include New Results from Subgroup Analysis of Cohort 1 Further Demonstrating Benefits of INOpulse

Predictive Oncology (NASDAQ: POAI) announces the availability of a broadcast titled, “New Hope in the Battle Against Ovarian Cancer.”